title: The effect of immunotherapy on the serum levels of eosinophil cationic protein in seasonal allergic rhinitis.
abstract: The role of serum eosinophil cationic protein levels in allergic rhinitis is controversial. It is also unclear whether with immunotherapy it is possible to reduce these serum levels in allergic diseases. We studied serum eosinophil cationic protein levels in patients with cedar-induced allergic rhinitis and compared them with non-atopic controls. The second aim of this study was to elucidate whether immunotherapy is capable of decreasing the seasonal elevation in serum eosinophil cationic protein levels in seasonal allergic rhinitis. The serum eosinophil cationic protein levels of the untreated patient group were significantly higher than those of the non-atopic controls. The levels in patients who received immunotherapy for 2 yr were also significantly higher than those of the non-atopic controls. However, the levels were not different between the patients undergoing immunotherapy for over 3 yr and the non-atopic controls. The serum levels of the 31 patients treated with immunotherapy correlated with the duration of immunotherapy. In conclusion, the serum eosinophil cationic protein levels are higher in untreated patients with seasonal allergic rhinitis and this seasonal activation in circulating eosiohophils decreases gradually during immunotherapy, but this inhibitory effect becomes apparent only after a number of years of immunotherapy. This prevention of seasonal eosinophil activation is one of the mechanisms responsible for the clinical effect of immunotherapy.
authors.affiliation: Department of Otolaryngology, Osaka City University Medical School, Abeno, Osaka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Y
authors.initials: Y
authors.lastname: Nakai
authors.forename: Y
authors.initials: Y
authors.lastname: Kakinoki
authors.forename: Y
authors.initials: Y
authors.lastname: Ohno
authors.forename: H
authors.initials: H
authors.lastname: Okamoto
authors.forename: H
authors.initials: H
authors.lastname: Sakamoto
authors.forename: A
authors.initials: A
authors.lastname: Kato
authors.forename: A
authors.initials: A
authors.lastname: Tanaka
mesh_terms: D000293:Adolescent; D000328:Adult; D000485:Allergens; D001798:Blood Proteins / Q000032:analysis*; D016022:Case-Control Studies; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000276:immunology*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007167:Immunotherapy; D018836:Inflammation Mediators / Q000097:blood*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000276:immunology / Q000627:therapeutic use; D011058:Pollen; D006255:Rhinitis, Allergic, Seasonal / Q000097:blood / Q000276:immunology / Q000628:therapy*; D012260:Ribonucleases; D013997:Time Factors; D014197:Trees
chemical_list: D000485:Allergens; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D018836:Inflammation Mediators; D010936:Plant Extracts; D007073:Immunoglobulin E; D012260:Ribonucleases